ONTOLOGY REPORT - ANNOTATIONS
| Term: | Urologic Neoplasms |
|
| Accession: | RDO:0005015
|
browse the term
|
| Definition: | Tumors or cancer of the URINARY TRACT in either the male or the female. |
| Synonyms: | exact_synonym: | Cancer of Urinary Tract; Cancer of the Urinary Tract; Urinary Tract Cancer; Urinary Tract Cancers; Urinary Tract Neoplasm; Urinary Tract Neoplasms; Urologic Cancer; Urologic Cancers; Urologic Neoplasm; Urological Cancer; Urological Cancers; Urological Neoplasm; Urological Neoplasms |
| | primary_id: | MESH:D014571 |
|
|
Urologic Neoplasms
|
| G |
Amacr |
alpha-methylacyl-CoA racemase |
|
Disease_progression |
ISS |
2 |
60,332,292 |
60,344,326 |
RGD:2315632 |
RGD |
| G |
Ang |
angiogenin, ribonuclease, RNase A family, 5 |
|
Disease_progression |
ISS |
15 |
27,083,089 |
27,083,526 |
RGD:2325710 |
RGD |
| G |
Aurka |
aurora kinase A |
|
Disease_progression |
ISS |
3 |
163,270,479 |
163,284,506 |
RGD:2293874 |
RGD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
Disease_progression |
ISS |
|
|
|
RGD:2293095 |
RGD |
| G |
Eno2 |
enolase 2, gamma, neuronal |
|
|
ISS |
4 |
160,891,003 |
160,897,723 |
RGD:2293741 |
RGD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
Disease_progression |
ISS |
10 |
87,219,157 |
87,242,919 |
RGD:2298503 |
RGD |
| G |
Hif1a |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
Disease_progression |
ISS |
6 |
96,419,024 |
96,463,891 |
RGD:2306226 |
RGD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
|
ISS |
19 |
37,251,147 |
37,266,040 |
RGD:2301044 |
RGD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
Disease_progression |
ISS |
13 |
64,427,288 |
64,432,978 |
RGD:2300126 |
RGD |
| G |
Rad50 |
RAD50 homolog (S. cerevisiae) |
|
|
ISS |
10 |
39,112,733 |
39,164,694 |
RGD:2293511 |
RGD |
| G |
Rhoa |
ras homolog family member A |
|
Disease_progression |
ISS |
|
|
|
RGD:1547861 |
RGD |
| G |
Sult1a1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
|
ISS |
1 |
185,829,205 |
185,832,725 |
RGD:2301044 |
RGD |
| G |
Tp63 |
tumor protein p63 |
|
Disease_progression |
ISS |
11 |
76,900,622 |
77,200,251 |
RGD:2315436 |
RGD |
| G |
Wnt2 |
wingless-type MMTV integration site family member 2 |
|
|
ISS |
4 |
43,649,783 |
43,689,596 |
RGD:2291877 |
RGD |
Carcinoma, Renal Cell
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
Disease_progression |
ISS |
4 |
21,709,855 |
21,796,628 |
RGD:2315557 |
RGD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
|
ISS |
4 |
21,709,855 |
21,796,628 |
RGD:2315559 |
RGD |
| G |
Abcg2 |
ATP-binding cassette, subfamily G (WHITE), member 2 |
|
Susceptibility |
ISS |
4 |
87,502,584 |
87,560,017 |
RGD:2315569 |
RGD |
| G |
Afp |
alpha-fetoprotein |
|
|
ISS |
14 |
19,092,563 |
19,110,728 |
RGD:2292042 |
RGD |
| G |
Agtr1a |
angiotensin II receptor, type 1a |
|
Severity |
ISS |
17 |
40,629,318 |
40,684,982 |
RGD:6903280 |
RGD |
| G |
Agtr2 |
angiotensin II receptor, type 2 |
|
Disease_progression |
ISS |
|
|
|
RGD:6903280 |
RGD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
|
ISS |
6 |
137,640,482 |
137,657,552 |
RGD:1643331 |
RGD |
| G |
Alox12 |
arachidonate 12-lipoxygenase |
|
|
ISS |
10 |
57,080,603 |
57,092,874 |
RGD:2315610 |
RGD |
| G |
Amacr |
alpha-methylacyl-CoA racemase |
|
|
ISS |
2 |
60,332,292 |
60,344,326 |
RGD:2315633 |
RGD |
| G |
Ang |
angiogenin, ribonuclease, RNase A family, 5 |
|
|
ISS |
15 |
27,083,089 |
27,083,526 |
RGD:2325699 |
RGD |
| G |
Angpt1 |
angiopoietin 1 |
|
Severity |
ISS |
7 |
78,195,504 |
78,451,471 |
RGD:1643335 |
RGD |
| G |
Apc |
adenomatous polyposis coli |
|
Onset |
ISS |
18 |
26,732,147 |
26,790,383 |
RGD:7242056 |
RGD |
| G |
Apc |
adenomatous polyposis coli |
|
Severity |
ISS |
18 |
26,732,147 |
26,790,383 |
RGD:7242059 |
RGD |
| G |
Apc |
adenomatous polyposis coli |
|
Disease_progression |
ISS |
18 |
26,732,147 |
26,790,383 |
RGD:7242060 |
RGD |
| G |
Aurka |
aurora kinase A |
|
|
ISS |
3 |
163,270,479 |
163,284,506 |
RGD:1643346 |
RGD |
| G |
Bad |
BCL2-associated agonist of cell death |
|
|
ISS |
1 |
209,617,373 |
209,626,292 |
RGD:2292677 |
RGD |
| G |
Bak1 |
BCL2-antagonist/killer 1 |
|
Severity |
ISS |
20 |
5,255,954 |
5,264,593 |
RGD:2315703 |
RGD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
Disease_progression |
ISS |
13 |
12,730,736 |
12,905,108 |
RGD:2293019 |
RGD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
|
ISS |
13 |
12,730,736 |
12,905,108 |
RGD:2298896 |
RGD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
|
ISS |
3 |
143,129,087 |
143,180,199 |
RGD:1643483 |
RGD |
| G |
Birc2 |
baculoviral IAP repeat-containing 2 |
|
Disease_progression |
ISS |
8 |
4,649,559 |
4,667,733 |
RGD:1643526 |
RGD |
| G |
Birc3 |
baculoviral IAP repeat-containing 3 |
|
|
ISS |
8 |
4,682,202 |
4,696,856 |
RGD:1643526 |
RGD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
Disease_progression |
ISS |
|
|
|
RGD:2293102 |
RGD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
|
ISS |
|
|
|
RGD:2293108 |
RGD |
| G |
Bmp4 |
bone morphogenetic protein 4 |
|
Severity |
ISS |
15 |
22,283,171 |
22,286,757 |
RGD:1643589 |
RGD |
| G |
Bmp6 |
bone morphogenetic protein 6 |
|
|
ISS |
17 |
32,380,199 |
32,689,295 |
RGD:7242419 |
RGD |
| G |
Bmp7 |
bone morphogenetic protein 7 |
|
Disease_progression |
ISS |
3 |
163,723,429 |
163,799,567 |
RGD:1643589 |
RGD |
| G |
Bsg |
basigin (Ok blood group) |
|
Disease_progression |
ISS |
7 |
11,507,914 |
11,515,132 |
RGD:2289052 |
RGD |
| G |
Btg2 |
BTG family, member 2 |
|
|
ISS |
13 |
47,026,986 |
47,030,745 |
RGD:2289069 |
RGD |
| G |
C4a |
complement component 4A (Rodgers blood group) |
|
Disease_progression |
ISS |
20 |
4,106,123 |
4,145,904 |
RGD:5688259 |
RGD |
| G |
C4b |
complement component 4B (Chido blood group) |
|
Disease_progression |
ISS |
20 |
4,300,687 |
4,315,882 |
RGD:5688259 |
RGD |
| G |
Car9 |
carbonic anhydrase 9 |
|
|
ISS |
5 |
59,986,413 |
59,993,015 |
RGD:2293199 |
RGD |
| G |
Car9 |
carbonic anhydrase 9 |
|
|
ISS |
5 |
59,986,413 |
59,993,015 |
RGD:2293201 |
RGD |
| G |
Car9 |
carbonic anhydrase 9 |
|
Disease_progression |
ISS |
5 |
59,986,413 |
59,993,015 |
RGD:2293191 |
RGD |
| G |
Car9 |
carbonic anhydrase 9 |
|
|
ISS |
5 |
59,986,413 |
59,993,015 |
RGD:2293198 |
RGD |
| G |
Casp3 |
caspase 3 |
|
|
ISS |
16 |
48,944,226 |
48,962,420 |
RGD:2293308 |
RGD |
| G |
Cav1 |
caveolin 1, caveolae protein |
|
Disease_progression |
ISS |
4 |
42,956,102 |
42,989,057 |
RGD:2289107 |
RGD |
| G |
Ccnb1 |
cyclin B1 |
|
Disease_progression |
ISS |
2 |
31,574,600 |
31,581,784 |
RGD:2315941 |
RGD |
| G |
Ccnd1 |
cyclin D1 |
|
|
ISS |
1 |
205,357,235 |
205,366,757 |
RGD:2289130 |
RGD |
| G |
Ccnd1 |
cyclin D1 |
|
|
ISS |
1 |
205,357,235 |
205,366,757 |
RGD:2289127 |
RGD |
| G |
Ccnd3 |
cyclin D3 |
|
Disease_progression |
ISS |
|
|
|
RGD:2316007 |
RGD |
| G |
Ccne1 |
cyclin E1 |
|
|
ISS |
1 |
90,568,189 |
90,577,426 |
RGD:2289228 |
RGD |
| G |
Cd44 |
Cd44 molecule |
|
Severity |
ISS |
3 |
88,022,962 |
88,110,352 |
RGD:2289351 |
RGD |
| G |
Cd44 |
Cd44 molecule |
|
Disease_progression |
ISS |
3 |
88,022,962 |
88,110,352 |
RGD:2289360 |
RGD |
| G |
Cd46 |
CD46 molecule, complement regulatory protein |
|
|
ISS |
13 |
110,972,812 |
111,003,407 |
RGD:2293550 |
RGD |
| G |
Cdh1 |
cadherin 1 |
|
Disease_progression |
ISS |
19 |
36,442,693 |
36,512,091 |
RGD:2289489 |
RGD |
| G |
Cdh1 |
cadherin 1 |
|
Onset |
ISS |
19 |
36,442,693 |
36,512,091 |
RGD:7242059 |
RGD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
|
ISS |
7 |
2,000,196 |
2,007,682 |
RGD:2293561 |
RGD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
|
ISS |
|
|
|
RGD:2293579 |
RGD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
Disease_progression |
ISS |
4 |
171,841,705 |
171,846,506 |
RGD:2293589 |
RGD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
Disease_progression |
ISS |
4 |
171,841,705 |
171,846,506 |
RGD:2289127 |
RGD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
|
ISS |
4 |
171,841,705 |
171,846,506 |
RGD:2293590 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
ISS |
5 |
108,908,749 |
108,916,380 |
RGD:2289680 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
ISS |
5 |
108,908,749 |
108,916,380 |
RGD:2289699 |
RGD |
| G |
Cdkn2a_v1 |
cyclin-dependent kinase inhibitor 2A, variant 1 |
|
|
ISS |
|
|
|
RGD:2289680 |
RGD |
| G |
Cdkn2a_v1 |
cyclin-dependent kinase inhibitor 2A, variant 1 |
|
|
ISS |
|
|
|
RGD:2289699 |
RGD |
| G |
Cdkn2a_v2 |
cyclin-dependent kinase inhibitor 2A, variant 2 |
|
|
ISS |
|
|
|
RGD:2289699 |
RGD |
| G |
Cdkn2a_v2 |
cyclin-dependent kinase inhibitor 2A, variant 2 |
|
|
ISS |
|
|
|
RGD:2289680 |
RGD |
| G |
Comt |
catechol-O-methyltransferase |
|
Susceptibility |
ISS |
11 |
84,561,591 |
84,581,713 |
RGD:2289716 |
RGD |
| G |
Crp |
C-reactive protein, pentraxin-related |
|
Disease_progression |
ISS |
13 |
88,702,243 |
88,703,153 |
RGD:6904212 |
RGD |
| G |
Csf1r |
colony stimulating factor 1 receptor |
|
|
ISS |
18 |
57,080,324 |
57,107,295 |
RGD:2299092 |
RGD |
| G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
|
|
ISS |
9 |
59,495,773 |
59,501,300 |
RGD:7204723 |
RGD |
| G |
Ctnna1 |
catenin (cadherin-associated protein), alpha 1, 102kDa |
|
Disease_progression |
ISS |
18 |
27,629,915 |
27,769,360 |
RGD:2289799 |
RGD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
Disease_progression |
ISS |
8 |
125,978,161 |
125,987,670 |
RGD:2289835 |
RGD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
Disease_progression |
ISS |
8 |
125,978,161 |
125,987,670 |
RGD:2289794 |
RGD |
| G |
Dirc2 |
disrupted in renal carcinoma 2 |
|
Susceptibility |
ISS |
11 |
66,829,715 |
66,910,201 |
RGD:1601072 |
RGD |
| G |
Dirc2 |
disrupted in renal carcinoma 2 |
|
|
ISS |
11 |
66,829,715 |
66,910,201 |
RGD:7240710 |
OMIM |
| G |
Ebag9 |
estrogen receptor binding site associated, antigen, 9 |
|
Disease_progression |
ISS |
7 |
80,515,272 |
80,533,346 |
RGD:2289852 |
RGD |
| G |
Egfr |
epidermal growth factor receptor |
|
|
ISS |
14 |
97,617,358 |
97,788,211 |
RGD:2293730 |
RGD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
|
ISS |
10 |
87,219,157 |
87,242,919 |
RGD:2289930 |
RGD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
|
ISS |
10 |
87,219,157 |
87,242,919 |
RGD:2289987 |
RGD |
| G |
Erbb4 |
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) |
|
|
ISS |
9 |
66,843,898 |
67,967,970 |
RGD:2289987 |
RGD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
|
ISS |
1 |
238,259,443 |
238,274,745 |
RGD:2290132 |
RGD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
|
ISS |
1 |
238,259,443 |
238,274,745 |
RGD:2290099 |
RGD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
|
ISS |
1 |
238,259,443 |
238,274,745 |
RGD:2290133 |
RGD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
|
ISS |
1 |
238,259,443 |
238,274,745 |
RGD:2290131 |
RGD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
|
ISS |
13 |
77,472,950 |
77,480,210 |
RGD:2290051 |
RGD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
|
ISS |
13 |
77,472,950 |
77,480,210 |
RGD:2290132 |
RGD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
Disease_progression |
ISS |
2 |
123,893,314 |
123,947,136 |
RGD:2290303 |
RGD |
| G |
Fh |
fumarate hydratase |
|
|
ISS |
13 |
91,329,837 |
91,355,722 |
RGD:6907135 |
RGD |
| G |
Fhit |
fragile histidine triad |
|
|
ISS |
15 |
15,823,461 |
17,329,184 |
RGD:2289870 |
RGD |
| G |
Fhit |
fragile histidine triad |
|
|
ISS |
15 |
15,823,461 |
17,329,184 |
RGD:2289903 |
RGD |
| G |
Flcn |
folliculin |
|
|
ISS |
10 |
46,110,527 |
46,129,613 |
RGD:7240710 |
OMIM |
| G |
Flt1 |
FMS-related tyrosine kinase 1 |
|
|
ISS |
12 |
7,858,092 |
8,035,966 |
RGD:2289960 |
RGD |
| G |
Flt1 |
FMS-related tyrosine kinase 1 |
|
|
ISS |
12 |
7,858,092 |
8,035,966 |
RGD:2301250 |
RGD |
| G |
Fn1 |
fibronectin 1 |
|
Severity |
ISS |
9 |
70,702,181 |
70,771,155 |
RGD:7205637 |
RGD |
| G |
Ghrh |
growth hormone releasing hormone |
|
|
ISS |
3 |
148,027,235 |
148,046,352 |
RGD:2301426 |
RGD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
Susceptibility |
ISS |
2 |
203,575,444 |
203,580,821 |
RGD:2293845 |
RGD |
| G |
Gstt1 |
glutathione S-transferase theta 1 |
|
Susceptibility |
ISS |
20 |
13,604,355 |
13,621,456 |
RGD:2293845 |
RGD |
| G |
Hif1a |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
Disease_progression |
ISS |
6 |
96,419,024 |
96,463,891 |
RGD:2306222 |
RGD |
| G |
Hnf1a |
HNF1 homeobox A |
|
|
ISS |
12 |
42,919,574 |
42,945,670 |
RGD:7240710 |
OMIM |
| G |
Hnf1b |
HNF1 homeobox B |
|
|
ISS |
10 |
72,081,091 |
72,187,014 |
RGD:7240710 |
OMIM |
| G |
Hoxb13 |
homeo box B13 |
|
Disease_progression |
ISS |
10 |
84,925,520 |
84,927,793 |
RGD:2314729 |
RGD |
| G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
|
|
ISS |
14 |
87,959,153 |
87,967,085 |
RGD:2290003 |
RGD |
| G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
|
|
IEP |
14 |
33,010,198 |
33,070,055 |
RGD:1626565 |
RGD |
| G |
Il1rn |
interleukin 1 receptor antagonist |
|
|
ISS |
3 |
2,607,800 |
2,613,216 |
RGD:6907413 |
RGD |
| G |
Il2 |
interleukin 2 |
|
|
ISS |
2 |
123,655,005 |
123,659,709 |
RGD:5147871 |
RGD |
| G |
Il4r |
interleukin 4 receptor |
|
Susceptibility |
ISS |
1 |
184,612,903 |
184,637,863 |
RGD:7207066 |
RGD |
| G |
Il4r |
interleukin 4 receptor |
|
Disease_progression |
ISS |
1 |
184,612,903 |
184,637,863 |
RGD:7207070 |
RGD |
| G |
Insr |
insulin receptor |
|
|
ISS |
12 |
2,934,967 |
3,087,691 |
RGD:2290462 |
RGD |
| G |
Jun |
jun proto-oncogene |
|
|
ISS |
5 |
115,358,166 |
115,361,259 |
RGD:1549443 |
RGD |
| G |
Jup |
junction plakoglobin |
|
|
ISS |
10 |
89,307,938 |
89,335,254 |
RGD:2291866 |
RGD |
| G |
Jup |
junction plakoglobin |
|
|
ISS |
10 |
89,307,938 |
89,335,254 |
RGD:2291890 |
RGD |
| G |
Kank1 |
KN motif and ankyrin repeat domains 1 |
|
|
ISS |
1 |
228,748,121 |
228,868,261 |
RGD:2315654 |
RGD |
| G |
Kdm6a |
lysine (K)-specific demethylase 6A |
|
|
ISS |
X |
15,926,055 |
16,052,872 |
RGD:6907133 |
RGD |
| G |
Kdm6a |
lysine (K)-specific demethylase 6A |
|
|
ISS |
X |
15,926,055 |
16,052,872 |
RGD:6907137 |
RGD |
| G |
Kdr |
kinase insert domain receptor |
|
|
ISS |
|
|
|
RGD:2301756 |
RGD |
| G |
Kit |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
|
|
ISS |
14 |
34,906,043 |
34,984,819 |
RGD:2292421 |
RGD |
| G |
Kit |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
|
|
ISS |
14 |
34,906,043 |
34,984,819 |
RGD:2292414 |
RGD |
| G |
Klk6 |
kallikrein related-peptidase 6 |
|
|
ISS |
1 |
94,254,350 |
94,261,500 |
RGD:2314864 |
RGD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
|
ISS |
4 |
182,869,242 |
182,895,106 |
RGD:2314914 |
RGD |
| G |
Lep |
leptin |
|
Resistance |
ISS |
4 |
55,943,837 |
55,945,938 |
RGD:6907119 |
RGD |
| G |
Lnpep |
leucyl/cystinyl aminopeptidase |
|
|
ISS |
1 |
56,063,361 |
56,151,257 |
RGD:2314919 |
RGD |
| G |
Ltf |
lactotransferrin |
|
|
ISS |
8 |
115,417,764 |
115,440,609 |
RGD:7243106 |
RGD |
| G |
Manf |
mesencephalic astrocyte-derived neurotrophic factor |
|
Susceptibility |
ISS |
8 |
112,111,358 |
112,113,311 |
RGD:1599220 |
RGD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
|
ISS |
8 |
68,379,074 |
68,451,554 |
RGD:2292629 |
RGD |
| G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
|
|
ISS |
8 |
68,379,074 |
68,451,554 |
RGD:2292630 |
RGD |
| G |
Met |
met proto-oncogene |
|
|
ISS |
4 |
43,134,183 |
43,211,355 |
RGD:1600122 |
RGD |
| G |
Mgp |
matrix Gla protein |
|
Disease_progression |
ISS |
4 |
173,910,595 |
173,913,917 |
RGD:2293578 |
RGD |
| G |
Mlh1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
|
ISS |
8 |
115,616,396 |
115,653,471 |
RGD:2293509 |
RGD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
Susceptibility |
ISS |
8 |
4,333,773 |
4,354,284 |
RGD:7207023 |
RGD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
No_Association |
ISS |
8 |
4,333,773 |
4,354,284 |
RGD:7207082 |
RGD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
|
ISS |
19 |
15,246,036 |
15,275,061 |
RGD:2290358 |
RGD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
Disease_progression |
ISS |
19 |
15,246,036 |
15,275,061 |
RGD:2290359 |
RGD |
| G |
Mmp3 |
matrix metallopeptidase 3 |
|
|
ISS |
8 |
4,315,601 |
4,329,146 |
RGD:7241233 |
RGD |
| G |
Mmp3 |
matrix metallopeptidase 3 |
|
|
ISS |
8 |
4,315,601 |
4,329,146 |
RGD:7207067 |
RGD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
|
ISS |
3 |
155,985,473 |
155,993,433 |
RGD:2290358 |
RGD |
| G |
Mok |
MOK protein kinase |
|
|
ISS |
6 |
135,531,656 |
135,562,497 |
RGD:7243170 |
RGD |
| G |
Msh2 |
mutS homolog 2 (E. coli) |
|
|
ISS |
6 |
11,199,906 |
11,258,350 |
RGD:2293509 |
RGD |
| G |
Mthfr |
methylenetetrahydrofolate reductase (NAD(P)H) |
|
Susceptibility |
ISS |
5 |
165,112,850 |
165,126,885 |
RGD:6893654 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
|
IEP |
7 |
98,953,142 |
98,958,060 |
RGD:7207841 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
|
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7207793 |
RGD |
| G |
Nf2 |
neurofibromin 2 (merlin) |
|
|
ISS |
14 |
85,415,142 |
85,508,807 |
RGD:2315000 |
RGD |
| G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
|
Disease_progression |
ISS |
10 |
82,591,705 |
82,601,075 |
RGD:2299059 |
RGD |
| G |
Nnmt |
nicotinamide N-methyltransferase |
|
|
ISS |
8 |
51,871,506 |
51,883,785 |
RGD:2299120 |
RGD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
Treatment |
ISS |
18 |
32,371,496 |
32,459,145 |
RGD:7174733 |
RGD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
Severity |
ISS |
18 |
32,371,496 |
32,459,145 |
RGD:7174727 |
RGD |
| G |
Ogg1 |
8-oxoguanine DNA glycosylase |
|
|
IEP |
4 |
149,209,745 |
149,219,081 |
RGD:2317140 |
RGD |
| G |
Ogg1 |
8-oxoguanine DNA glycosylase |
|
|
ISS |
4 |
149,209,745 |
149,219,081 |
RGD:1600295 |
RGD |
| G |
Ogg1 |
8-oxoguanine DNA glycosylase |
|
|
ISS |
4 |
149,209,745 |
149,219,081 |
RGD:7240710 |
OMIM |
| G |
Pak1 |
p21 protein (Cdc42/Rac)-activated kinase 1 |
|
|
ISS |
1 |
155,057,622 |
155,174,714 |
RGD:2299159 |
RGD |
| G |
Pbrm1 |
polybromo 1 |
|
|
ISS |
16 |
6,456,202 |
6,550,030 |
RGD:6907133 |
RGD |
| G |
Pbrm1 |
polybromo 1 |
|
|
ISS |
16 |
6,456,202 |
6,550,030 |
RGD:6907137 |
RGD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
Severity |
ISS |
3 |
120,008,715 |
120,012,589 |
RGD:2315008 |
RGD |
| G |
Pdgfra |
platelet derived growth factor receptor, alpha polypeptide |
|
Disease_progression |
ISS |
14 |
35,369,422 |
35,418,126 |
RGD:2292157 |
RGD |
| G |
Pdgfrb |
platelet derived growth factor receptor, beta polypeptide |
|
|
ISS |
18 |
57,014,475 |
57,053,581 |
RGD:2292198 |
RGD |
| G |
Pdgfrb |
platelet derived growth factor receptor, beta polypeptide |
|
|
ISS |
18 |
57,014,475 |
57,053,581 |
RGD:2290496 |
RGD |
| G |
Pdpn |
podoplanin |
|
Disease_progression |
ISS |
5 |
162,142,251 |
162,175,921 |
RGD:2292239 |
RGD |
| G |
Plau |
plasminogen activator, urokinase |
|
Severity |
ISS |
15 |
3,680,072 |
3,686,232 |
RGD:7241133 |
RGD |
| G |
Pld2 |
phospholipase D2 |
|
|
ISS |
10 |
57,388,474 |
57,439,063 |
RGD:2299898 |
RGD |
| G |
Pmepa1 |
prostate transmembrane protein, androgen induced 1 |
|
|
ISS |
3 |
164,094,654 |
164,140,142 |
RGD:2315108 |
RGD |
| G |
Prcc |
papillary renal cell carcinoma (translocation-associated) |
|
|
ISS |
2 |
179,931,933 |
179,957,464 |
RGD:7240710 |
OMIM |
| G |
Pten |
phosphatase and tensin homolog |
|
Disease_progression |
ISS |
1 |
236,771,027 |
236,837,261 |
RGD:2292513 |
RGD |
| G |
Pten |
phosphatase and tensin homolog |
|
|
ISS |
1 |
236,771,027 |
236,837,261 |
RGD:2292500 |
RGD |
| G |
Pten |
phosphatase and tensin homolog |
|
|
ISS |
1 |
236,771,027 |
236,837,261 |
RGD:1643331 |
RGD |
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
|
IEP |
3 |
15,343,832 |
15,365,412 |
RGD:2300212 |
RGD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
Disease_progression |
ISS |
13 |
64,427,288 |
64,432,978 |
RGD:2300204 |
RGD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
|
IEP |
13 |
64,427,288 |
64,432,978 |
RGD:2300212 |
RGD |
| G |
Rassf1 |
Ras association (RalGDS/AF-6) domain family member 1 |
|
|
ISS |
8 |
112,798,863 |
112,810,004 |
RGD:2299866 |
RGD |
| G |
Rassf1 |
Ras association (RalGDS/AF-6) domain family member 1 |
|
|
ISS |
8 |
112,798,863 |
112,810,004 |
RGD:2291977 |
RGD |
| G |
Rb1 |
retinoblastoma 1 |
|
Disease_progression |
ISS |
15 |
53,828,881 |
53,962,099 |
RGD:2299893 |
RGD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
|
ISS |
1 |
208,262,669 |
208,273,148 |
RGD:2298771 |
RGD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
|
ISS |
1 |
208,262,669 |
208,273,148 |
RGD:2298755 |
RGD |
| G |
Rnf139 |
ring finger protein 139 |
|
|
ISS |
7 |
95,659,052 |
95,661,624 |
RGD:1599629 |
RGD |
| G |
Rnf139 |
ring finger protein 139 |
|
|
ISS |
7 |
95,659,052 |
95,661,624 |
RGD:2289870 |
RGD |
| G |
Rnf139 |
ring finger protein 139 |
|
|
ISS |
7 |
95,659,052 |
95,661,624 |
RGD:7240710 |
OMIM |
| G |
RT1-Db1 |
RT1 class II, locus Db1 |
|
Disease_progression |
ISS |
20 |
4,671,489 |
4,681,058 |
RGD:2314695 |
RGD |
| G |
RT1-Db1 |
RT1 class II, locus Db1 |
|
Susceptibility |
ISS |
20 |
4,671,489 |
4,681,058 |
RGD:2314704 |
RGD |
| G |
RT1-Db1 |
RT1 class II, locus Db1 |
|
Susceptibility |
ISS |
20 |
4,671,489 |
4,681,058 |
RGD:2314701 |
RGD |
| G |
Sdhb |
succinate dehydrogenase complex, subunit B, iron sulfur (Ip) |
|
|
ISS |
5 |
159,818,669 |
159,839,772 |
RGD:6907134 |
RGD |
| G |
Sdhd |
succinate dehydrogenase complex, subunit D, integral membrane protein |
|
|
ISS |
8 |
53,955,067 |
53,964,547 |
RGD:6907134 |
RGD |
| G |
Setd2 |
SET domain containing 2 |
|
|
ISS |
8 |
114,913,851 |
114,999,955 |
RGD:6907133 |
RGD |
| G |
Setd2 |
SET domain containing 2 |
|
|
ISS |
8 |
114,913,851 |
114,999,955 |
RGD:6907137 |
RGD |
| G |
Sfrp1 |
secreted frizzled-related protein 1 |
|
|
ISS |
16 |
73,030,458 |
73,067,304 |
RGD:4107084 |
RGD |
| G |
Skp2 |
S-phase kinase-associated protein 2, E3 ubiquitin protein ligase |
|
Disease_progression |
ISS |
2 |
58,769,164 |
58,797,229 |
RGD:2315038 |
RGD |
| G |
Smad2 |
SMAD family member 2 |
|
Severity |
ISS |
18 |
73,180,520 |
73,241,707 |
RGD:2299973 |
RGD |
| G |
Smad4 |
SMAD family member 4 |
|
Severity |
ISS |
18 |
70,432,705 |
70,461,541 |
RGD:2299973 |
RGD |
| G |
Sparc |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
|
ISS |
10 |
40,809,730 |
40,831,481 |
RGD:2300025 |
RGD |
| G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
|
|
ISS |
18 |
37,090,934 |
37,099,835 |
RGD:2300388 |
RGD |
| G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
|
Disease_progression |
ISS |
18 |
37,090,934 |
37,099,835 |
RGD:2300387 |
RGD |
| G |
St14 |
suppression of tumorigenicity 14 (colon carcinoma) |
|
|
ISS |
8 |
30,916,769 |
30,932,214 |
RGD:2315090 |
RGD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
|
ISS |
10 |
89,821,078 |
89,872,970 |
RGD:2291913 |
RGD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
Disease_progression |
ISS |
10 |
89,821,078 |
89,872,970 |
RGD:2291917 |
RGD |
| G |
Terc |
telomerase RNA component |
|
|
ISS |
2 |
117,234,446 |
117,234,833 |
RGD:2291972 |
RGD |
| G |
Tert |
telomerase reverse transcriptase |
|
|
ISS |
1 |
30,445,180 |
30,465,942 |
RGD:2291980 |
RGD |
| G |
Tfe3 |
transcription factor binding to IGHM enhancer 3 |
|
|
ISS |
X |
26,768,875 |
26,781,006 |
RGD:1599384 |
RGD |
| G |
Tfrc |
transferrin receptor |
|
|
ISS |
11 |
69,976,258 |
69,998,098 |
RGD:2292024 |
RGD |
| G |
Tfrc |
transferrin receptor |
|
|
ISS |
11 |
69,976,258 |
69,998,098 |
RGD:2292025 |
RGD |
| G |
Thra |
thyroid hormone receptor alpha |
|
|
ISS |
10 |
87,514,443 |
87,542,306 |
RGD:2315097 |
RGD |
| G |
Thrb |
thyroid hormone receptor beta |
|
|
ISS |
15 |
9,282,845 |
9,345,506 |
RGD:2315097 |
RGD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
Disease_progression |
ISS |
X |
12,542,496 |
12,547,094 |
RGD:2290350 |
RGD |
| G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
|
Disease_progression |
ISS |
10 |
108,310,473 |
108,358,821 |
RGD:2290359 |
RGD |
| G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
|
|
ISS |
10 |
108,310,473 |
108,358,821 |
RGD:2290358 |
RGD |
| G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
|
|
ISS |
7 |
19,677,144 |
19,727,072 |
RGD:2290421 |
RGD |
| G |
Timp4 |
tissue inhibitor of metalloproteinase 4 |
|
|
ISS |
4 |
151,375,072 |
151,381,591 |
RGD:2290421 |
RGD |
| G |
Tnf |
tumor necrosis factor |
|
|
ISS |
20 |
3,661,000 |
3,663,618 |
RGD:2315119 |
RGD |
| G |
Tnf |
tumor necrosis factor |
|
|
ISS |
20 |
3,661,000 |
3,663,618 |
RGD:2315113 |
RGD |
| G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
|
|
ISS |
15 |
50,138,439 |
50,163,254 |
RGD:2290496 |
RGD |
| G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
|
|
ISS |
15 |
50,138,439 |
50,163,254 |
RGD:2290491 |
RGD |
| G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
|
|
ISS |
4 |
162,172,563 |
162,185,252 |
RGD:5131437 |
RGD |
| G |
Tp53 |
tumor protein p53 |
|
Disease_progression |
ISS |
10 |
56,399,721 |
56,411,150 |
RGD:2290544 |
RGD |
| G |
Tp73 |
tumor protein p73 |
|
|
ISS |
5 |
170,848,979 |
171,078,739 |
RGD:2291837 |
RGD |
| G |
Txnip |
thioredoxin interacting protein |
|
|
IED |
2 |
191,356,954 |
191,360,757 |
RGD:1642756 |
RGD |
| G |
Tymp |
thymidine phosphorylase |
|
Severity |
ISS |
7 |
127,666,518 |
127,671,624 |
RGD:2293723 |
RGD |
| G |
Tymp |
thymidine phosphorylase |
|
|
ISS |
7 |
127,666,518 |
127,671,624 |
RGD:2293717 |
RGD |
| G |
Vdr |
vitamin D (1,25- dihydroxyvitamin D3) receptor |
|
|
IEA |
7 |
136,567,614 |
136,617,280 |
RGD:1331525 |
RGD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
Disease_progression |
ISS |
9 |
10,520,730 |
10,536,071 |
RGD:2315455 |
RGD |
| G |
Vegfc |
vascular endothelial growth factor C |
|
|
ISS |
16 |
40,624,435 |
40,739,692 |
RGD:2315476 |
RGD |
| G |
Vhl |
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
|
|
ISS |
4 |
149,529,396 |
149,536,289 |
RGD:6907133 |
RGD |
| G |
Vhl |
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
|
|
ISS |
4 |
149,529,396 |
149,536,289 |
RGD:1580367 |
RGD |
| G |
Vhl |
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
|
|
ISS |
4 |
149,529,396 |
149,536,289 |
RGD:7240710 |
OMIM |
| G |
Vwf |
von Willebrand factor |
|
Disease_progression |
ISS |
4 |
161,723,415 |
161,854,766 |
RGD:7207032 |
RGD |
| G |
Wif1 |
Wnt inhibitory factor 1 |
|
|
ISS |
7 |
60,330,517 |
60,400,697 |
RGD:2291869 |
RGD |
| G |
Wnt11 |
wingless-type MMTV integration site family, member 11 |
|
|
ISS |
1 |
156,125,969 |
156,142,065 |
RGD:2299947 |
RGD |
| G |
Xiap |
X-linked inhibitor of apoptosis |
|
Disease_progression |
ISS |
X |
3,011,520 |
3,047,798 |
RGD:2315854 |
RGD |
| G |
Xrcc1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
|
Susceptibility |
ISS |
1 |
79,834,167 |
79,860,300 |
RGD:2302577 |
RGD |
| S |
Ni/Hin |
|
|
|
IED |
|
|
|
RGD:628433 |
RGD |
Clear-cell metastatic renal cell carcinoma
|
| G |
F2 |
coagulation factor II |
|
|
ISS |
3 |
76,005,318 |
76,018,603 |
RGD:6893520 |
RGD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
|
ISS |
1 |
206,627,398 |
206,629,866 |
RGD:6906878 |
RGD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
|
ISS |
1 |
122,704,976 |
122,990,007 |
RGD:7242921 |
RGD |
| G |
Mmp12 |
matrix metallopeptidase 12 |
|
|
ISS |
8 |
4,249,938 |
4,259,675 |
RGD:2290421 |
RGD |
| G |
Mthfr |
methylenetetrahydrofolate reductase (NAD(P)H) |
|
Susceptibility |
ISS |
5 |
165,112,850 |
165,126,885 |
RGD:6893474 |
RGD |
| G |
Mthfr |
methylenetetrahydrofolate reductase (NAD(P)H) |
|
Severity |
ISS |
5 |
165,112,850 |
165,126,885 |
RGD:6893632 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
Severity |
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7207420 |
RGD |
Denys-Drash Syndrome
|
| G |
Ar |
androgen receptor |
|
|
ISS |
X |
85,949,507 |
86,119,199 |
RGD:1643343 |
RGD |
| G |
Wt1 |
Wilms tumor 1 |
|
|
ISS |
3 |
90,529,704 |
90,577,280 |
RGD:1580624 |
RGD |
| G |
Wt1 |
Wilms tumor 1 |
|
|
ISS |
3 |
90,529,704 |
90,577,280 |
RGD:7240710 |
OMIM |
Kidney Neoplasms
|
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
|
ISS |
6 |
137,640,482 |
137,657,552 |
RGD:1643332 |
RGD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
Disease_progression |
ISS |
|
|
|
RGD:2293109 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
IAGP |
5 |
108,908,749 |
108,916,380 |
RGD:1298747 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
ISS |
5 |
108,908,749 |
108,916,380 |
RGD:2289679 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
ISS |
5 |
108,908,749 |
108,916,380 |
RGD:2289689 |
RGD |
| G |
Cdkn2a_v1 |
cyclin-dependent kinase inhibitor 2A, variant 1 |
|
|
ISS |
|
|
|
RGD:2289679 |
RGD |
| G |
Eno2 |
enolase 2, gamma, neuronal |
|
|
ISS |
4 |
160,891,003 |
160,897,723 |
RGD:2293736 |
RGD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
|
ISS |
10 |
87,219,157 |
87,242,919 |
RGD:2289934 |
RGD |
| G |
Fh |
fumarate hydratase |
|
|
ISS |
13 |
91,329,837 |
91,355,722 |
RGD:1598939 |
RGD |
| G |
Flcn |
folliculin |
|
|
ISS |
10 |
46,110,527 |
46,129,613 |
RGD:1598946 |
RGD |
| G |
Flcn |
folliculin |
|
|
IAGP |
10 |
46,110,527 |
46,129,613 |
RGD:1302869 |
RGD |
| G |
Flt1 |
FMS-related tyrosine kinase 1 |
|
Severity |
ISS |
12 |
7,858,092 |
8,035,966 |
RGD:2289948 |
RGD |
| G |
Fosl1 |
fos-like antigen 1 |
|
|
IEP |
1 |
208,090,612 |
208,099,118 |
RGD:2293758 |
RGD |
| G |
Fosl2 |
fos-like antigen 2 |
|
|
IEP |
|
|
|
RGD:2293758 |
RGD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
Susceptibility |
ISS |
2 |
203,575,444 |
203,580,821 |
RGD:2293828 |
RGD |
| G |
Gstt1 |
glutathione S-transferase theta 1 |
|
Susceptibility |
ISS |
20 |
13,604,355 |
13,621,456 |
RGD:2293828 |
RGD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
|
IEP |
1 |
122,704,976 |
122,990,007 |
RGD:7242846 |
RGD |
| G |
Itgb2 |
integrin, beta 2 |
|
|
ISS |
20 |
11,446,521 |
11,485,009 |
RGD:6907072 |
RGD |
| G |
Jun |
jun proto-oncogene |
|
|
IEP |
5 |
115,358,166 |
115,361,259 |
RGD:2293758 |
RGD |
| G |
Junb |
jun B proto-oncogene |
|
|
IEP |
19 |
24,831,536 |
24,833,320 |
RGD:2293758 |
RGD |
| G |
Jund |
jun D proto-oncogene |
|
|
IEP |
16 |
19,239,694 |
19,241,529 |
RGD:2293758 |
RGD |
| G |
Kdr |
kinase insert domain receptor |
|
|
ISS |
|
|
|
RGD:2301759 |
RGD |
| G |
Letmd1 |
LETM1 domain containing 1 |
|
|
ISS |
7 |
139,172,373 |
139,181,857 |
RGD:2314918 |
RGD |
| G |
Met |
met proto-oncogene |
|
|
ISS |
4 |
43,134,183 |
43,211,355 |
RGD:1600122 |
RGD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
|
ISS |
8 |
4,333,773 |
4,354,284 |
RGD:7207056 |
RGD |
| G |
Plau |
plasminogen activator, urokinase |
|
|
ISS |
15 |
3,680,072 |
3,686,232 |
RGD:7241213 |
RGD |
| G |
Ppargc1a |
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha |
|
|
ISS |
14 |
64,278,115 |
64,370,912 |
RGD:7242016 |
RGD |
| G |
Ppat |
phosphoribosyl pyrophosphate amidotransferase |
|
|
IEP |
14 |
33,509,364 |
33,543,743 |
RGD:5135050 |
RGD |
| G |
Rassf1 |
Ras association (RalGDS/AF-6) domain family member 1 |
|
|
ISS |
8 |
112,798,863 |
112,810,004 |
RGD:2291979 |
RGD |
| G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
|
|
ISS |
1 |
42,351,239 |
42,378,295 |
RGD:7243178 |
RGD |
| G |
Slc22a2 |
solute carrier family 22 (organic cation transporter), member 2 |
|
|
ISS |
1 |
42,395,676 |
42,442,847 |
RGD:7243178 |
RGD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
|
ISS |
1 |
42,690,158 |
42,781,895 |
RGD:7243178 |
RGD |
| G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
|
|
ISS |
7 |
19,677,144 |
19,727,072 |
RGD:2290419 |
RGD |
| G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
|
|
ISS |
15 |
50,138,439 |
50,163,254 |
RGD:2290497 |
RGD |
| G |
Top2a |
topoisomerase (DNA) II alpha |
|
Disease_progression |
ISS |
10 |
87,771,337 |
87,800,960 |
RGD:2315122 |
RGD |
| G |
Vangl2 |
VANGL planar cell polarity protein 2 |
|
|
ISS |
13 |
87,964,426 |
87,988,364 |
RGD:2298799 |
RGD |
| G |
Vhl |
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
|
|
IEP |
4 |
149,529,396 |
149,536,289 |
RGD:625549 |
RGD |
Leiomyomatosis and renal cell cancer, hereditary
|
| G |
Fh |
fumarate hydratase |
|
|
ISS |
13 |
91,329,837 |
91,355,722 |
RGD:7240710 |
OMIM |
Papillary renal cell carcinoma, sporadic
|
| G |
Myc |
myelocytomatosis oncogene |
|
|
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7240562 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
|
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7240563 |
RGD |
Rhabdoid Tumor Predisposition Syndrome 1
|
| G |
Smarcb1 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 |
|
|
ISS |
20 |
13,140,331 |
13,162,437 |
RGD:7240710 |
OMIM |
Urinary Bladder Neoplasms
|
| G |
Acacb |
acetyl-CoA carboxylase beta |
|
|
ISS |
12 |
43,388,679 |
43,492,993 |
RGD:1300333 |
RGD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
Disease_progression |
ISS |
6 |
137,640,482 |
137,657,552 |
RGD:2291891 |
RGD |
| G |
Alox12 |
arachidonate 12-lipoxygenase |
|
|
ISS |
10 |
57,080,603 |
57,092,874 |
RGD:2315608 |
RGD |
| G |
Amacr |
alpha-methylacyl-CoA racemase |
|
Severity |
ISS |
2 |
60,332,292 |
60,344,326 |
RGD:2315629 |
RGD |
| G |
Ang |
angiogenin, ribonuclease, RNase A family, 5 |
|
|
ISS |
15 |
27,083,089 |
27,083,526 |
RGD:2325700 |
RGD |
| G |
Ang |
angiogenin, ribonuclease, RNase A family, 5 |
|
|
ISS |
15 |
27,083,089 |
27,083,526 |
RGD:2325704 |
RGD |
| G |
Apex1 |
APEX nuclease (multifunctional DNA repair enzyme) 1 |
|
Susceptibility |
ISS |
15 |
26,904,124 |
26,906,224 |
RGD:2315660 |
RGD |
| G |
Areg |
amphiregulin |
|
|
ISS |
14 |
18,466,313 |
18,475,571 |
RGD:2292662 |
RGD |
| G |
Areg |
amphiregulin |
|
Disease_progression |
ISS |
14 |
18,466,313 |
18,475,571 |
RGD:2292661 |
RGD |
| G |
Aurka |
aurora kinase A |
|
Disease_progression |
ISS |
3 |
163,270,479 |
163,284,506 |
RGD:2293871 |
RGD |
| G |
Bax |
Bcl2-associated X protein |
|
|
ISS |
1 |
95,933,023 |
95,938,176 |
RGD:2296023 |
RGD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
Severity |
ISS |
13 |
12,730,736 |
12,905,108 |
RGD:2292910 |
RGD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
|
ISS |
13 |
12,730,736 |
12,905,108 |
RGD:2293014 |
RGD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
Disease_progression |
ISS |
3 |
143,129,087 |
143,180,199 |
RGD:2292910 |
RGD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
Disease_progression |
ISS |
|
|
|
RGD:2293096 |
RGD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
|
ISS |
|
|
|
RGD:2293094 |
RGD |
| G |
Brca1 |
breast cancer 1, early onset |
|
|
ISS |
10 |
90,513,630 |
90,572,676 |
RGD:2293014 |
RGD |
| G |
Car9 |
carbonic anhydrase 9 |
|
Disease_progression |
ISS |
5 |
59,986,413 |
59,993,015 |
RGD:2293197 |
RGD |
| G |
Casp3 |
caspase 3 |
|
Disease_progression |
ISS |
16 |
48,944,226 |
48,962,420 |
RGD:2298949 |
RGD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
Disease_progression |
ISS |
5 |
160,704,234 |
160,721,796 |
RGD:2315930 |
RGD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
Susceptibility |
ISS |
5 |
160,704,234 |
160,721,796 |
RGD:2315929 |
RGD |
| G |
Cav1 |
caveolin 1, caveolae protein |
|
Severity |
ISS |
4 |
42,956,102 |
42,989,057 |
RGD:2289110 |
RGD |
| G |
Ccnd3 |
cyclin D3 |
|
Disease_progression |
ISS |
|
|
|
RGD:2316012 |
RGD |
| G |
Ccne1 |
cyclin E1 |
|
Severity |
ISS |
1 |
90,568,189 |
90,577,426 |
RGD:2289267 |
RGD |
| G |
Ccne1 |
cyclin E1 |
|
Disease_progression |
ISS |
1 |
90,568,189 |
90,577,426 |
RGD:2296035 |
RGD |
| G |
Cd44 |
Cd44 molecule |
|
|
ISS |
3 |
88,022,962 |
88,110,352 |
RGD:2289357 |
RGD |
| G |
Cd82 |
Cd82 molecule |
|
|
ISS |
3 |
77,831,771 |
77,875,764 |
RGD:2289391 |
RGD |
| G |
Cd82 |
Cd82 molecule |
|
Disease_progression |
ISS |
3 |
77,831,771 |
77,875,764 |
RGD:2289401 |
RGD |
| G |
Cd9 |
CD9 molecule |
|
Disease_progression |
ISS |
4 |
162,279,462 |
162,312,889 |
RGD:2326207 |
RGD |
| G |
Cdc25a |
cell division cycle 25A |
|
|
ISS |
8 |
114,237,704 |
114,255,971 |
RGD:2715645 |
RGD |
| G |
Cdc25b |
cell division cycle 25B |
|
Disease_progression |
ISS |
3 |
118,893,716 |
118,903,516 |
RGD:2739695 |
RGD |
| G |
Cdh1 |
cadherin 1 |
|
|
IEP |
19 |
36,442,693 |
36,512,091 |
RGD:1599549 |
RGD |
| G |
Cdh1 |
cadherin 1 |
|
Disease_progression |
ISS |
19 |
36,442,693 |
36,512,091 |
RGD:2289491 |
RGD |
| G |
Cdh13 |
cadherin 13 |
|
|
ISS |
19 |
48,507,173 |
49,575,123 |
RGD:2293014 |
RGD |
| G |
Cdk1 |
cyclin-dependent kinase 1 |
|
|
ISS |
20 |
20,018,044 |
20,044,030 |
RGD:2715645 |
RGD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
Disease_progression |
ISS |
|
|
|
RGD:2299056 |
RGD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
|
IEP |
|
|
|
RGD:2289144 |
RGD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
Susceptibility |
ISS |
4 |
171,841,705 |
171,846,506 |
RGD:2293595 |
RGD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
Disease_progression |
ISS |
4 |
171,841,705 |
171,846,506 |
RGD:2293592 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
ISS |
5 |
108,908,749 |
108,916,380 |
RGD:2296048 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
ISS |
5 |
108,908,749 |
108,916,380 |
RGD:2289687 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
ISS |
5 |
108,908,749 |
108,916,380 |
RGD:2296052 |
RGD |
| G |
Cdkn2a_v1 |
cyclin-dependent kinase inhibitor 2A, variant 1 |
|
|
ISS |
|
|
|
RGD:2289687 |
RGD |
| G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) |
|
|
ISS |
5 |
108,939,669 |
108,945,293 |
RGD:2289696 |
RGD |
| G |
Chek2 |
checkpoint kinase 2 |
|
Susceptibility |
ISS |
12 |
45,933,900 |
45,965,427 |
RGD:2289704 |
RGD |
| G |
Comt |
catechol-O-methyltransferase |
|
|
ISS |
11 |
84,561,591 |
84,581,713 |
RGD:2289726 |
RGD |
| G |
Ctnna1 |
catenin (cadherin-associated protein), alpha 1, 102kDa |
|
Disease_progression |
ISS |
18 |
27,629,915 |
27,769,360 |
RGD:2289491 |
RGD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
Disease_progression |
ISS |
8 |
125,978,161 |
125,987,670 |
RGD:2289829 |
RGD |
| G |
Ctsb |
cathepsin B |
|
|
ISS |
15 |
42,402,829 |
42,423,701 |
RGD:2315615 |
RGD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
|
ISS |
1 |
243,281,320 |
243,320,945 |
RGD:6903918 |
RGD |
| G |
Dapk3 |
death-associated protein kinase 3 |
|
|
ISS |
7 |
10,007,997 |
10,016,365 |
RGD:734875 |
RGD |
| G |
Dbc1 |
deleted in bladder cancer 1 |
|
|
ISS |
5 |
86,070,267 |
86,216,181 |
RGD:1300390 |
RGD |
| G |
Dnmt1 |
DNA (cytosine-5-)-methyltransferase 1 |
|
|
ISS |
8 |
19,926,995 |
19,973,256 |
RGD:2301220 |
RGD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
Disease_progression |
ISS |
10 |
16,942,913 |
16,945,696 |
RGD:2298694 |
RGD |
| G |
Egfr |
epidermal growth factor receptor |
|
Disease_progression |
ISS |
14 |
97,617,358 |
97,788,211 |
RGD:2298502 |
RGD |
| G |
Egfr |
epidermal growth factor receptor |
|
Disease_progression |
ISS |
14 |
97,617,358 |
97,788,211 |
RGD:2289943 |
RGD |
| G |
Eno2 |
enolase 2, gamma, neuronal |
|
|
ISS |
4 |
160,891,003 |
160,897,723 |
RGD:2293738 |
RGD |
| G |
Ephx1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
Disease_progression |
ISS |
13 |
96,722,973 |
96,752,940 |
RGD:2315930 |
RGD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
Disease_progression |
ISS |
10 |
87,219,157 |
87,242,919 |
RGD:2298502 |
RGD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
|
ISS |
10 |
87,219,157 |
87,242,919 |
RGD:2289934 |
RGD |
| G |
Erbb3 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) |
|
Disease_progression |
ISS |
7 |
1,858,057 |
1,877,353 |
RGD:2298502 |
RGD |
| G |
Erbb4 |
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) |
|
Disease_progression |
ISS |
9 |
66,843,898 |
67,967,970 |
RGD:2298502 |
RGD |
| G |
Erbb4 |
v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) |
|
Disease_progression |
ISS |
9 |
66,843,898 |
67,967,970 |
RGD:2289943 |
RGD |
| G |
F2 |
coagulation factor II |
|
Severity |
ISS |
3 |
76,005,318 |
76,018,603 |
RGD:6893573 |
RGD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
Susceptibility |
ISS |
1 |
238,259,443 |
238,274,745 |
RGD:2290063 |
RGD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
Susceptibility |
ISS |
13 |
77,472,950 |
77,480,210 |
RGD:2290063 |
RGD |
| G |
Fgf1 |
fibroblast growth factor 1 (acidic) |
|
|
ISS |
18 |
31,785,480 |
31,806,452 |
RGD:2290291 |
RGD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
|
ISS |
2 |
123,893,314 |
123,947,136 |
RGD:2290291 |
RGD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
|
ISS |
1 |
189,482,975 |
189,589,279 |
RGD:2301193 |
RGD |
| G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
|
ISS |
1 |
189,482,975 |
189,589,279 |
RGD:2289664 |
RGD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
|
ISS |
14 |
82,683,191 |
82,697,229 |
RGD:2289864 |
RGD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
Disease_progression |
ISS |
14 |
82,683,191 |
82,697,229 |
RGD:2301224 |
RGD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
Severity |
ISS |
14 |
82,683,191 |
82,697,229 |
RGD:2301223 |
RGD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
|
ISS |
14 |
82,683,191 |
82,697,229 |
RGD:2301222 |
RGD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
Disease_progression |
ISS |
14 |
82,683,191 |
82,697,229 |
RGD:2301225 |
RGD |
| G |
Fgfr3 |
fibroblast growth factor receptor 3 |
|
|
ISS |
14 |
82,683,191 |
82,697,229 |
RGD:7240710 |
OMIM |
| G |
Fhit |
fragile histidine triad |
|
|
ISS |
15 |
15,823,461 |
17,329,184 |
RGD:2301233 |
RGD |
| G |
Fhit |
fragile histidine triad |
|
|
ISS |
15 |
15,823,461 |
17,329,184 |
RGD:2289897 |
RGD |
| G |
Fhit |
fragile histidine triad |
|
|
ISS |
15 |
15,823,461 |
17,329,184 |
RGD:2301232 |
RGD |
| G |
Figf |
c-fos induced growth factor |
|
Disease_progression |
ISS |
X |
50,830,612 |
50,864,445 |
RGD:2315479 |
RGD |
| G |
Fn1 |
fibronectin 1 |
|
|
ISS |
9 |
70,702,181 |
70,771,155 |
RGD:7205680 |
RGD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
Susceptibility |
ISS |
2 |
203,575,444 |
203,580,821 |
RGD:6906879 |
RGD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
|
ISS |
1 |
206,627,398 |
206,629,866 |
RGD:6906883 |
RGD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
Contributes_to |
ISS |
1 |
206,627,398 |
206,629,866 |
RGD:6906879 |
RGD |
| G |
Gstt1 |
glutathione S-transferase theta 1 |
|
Susceptibility |
ISS |
20 |
13,604,355 |
13,621,456 |
RGD:6906879 |
RGD |
| G |
H19 |
H19, imprinted maternally expressed transcript (non-protein coding) |
|
|
ISS |
1 |
202,822,925 |
202,825,601 |
RGD:2306168 |
RGD |
| G |
H19 |
H19, imprinted maternally expressed transcript (non-protein coding) |
|
|
ISS |
1 |
202,822,925 |
202,825,601 |
RGD:2306184 |
RGD |
| G |
H19 |
H19, imprinted maternally expressed transcript (non-protein coding) |
|
|
ISS |
1 |
202,822,925 |
202,825,601 |
RGD:2306171 |
RGD |
| G |
H19 |
H19, imprinted maternally expressed transcript (non-protein coding) |
|
|
ISS |
1 |
202,822,925 |
202,825,601 |
RGD:2306180 |
RGD |
| G |
Hmbs |
hydroxymethylbilane synthase |
|
|
ISS |
8 |
47,314,235 |
47,321,604 |
RGD:2301681 |
RGD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
Disease_progression |
ISS |
1 |
201,385,705 |
201,388,987 |
RGD:2314833 |
RGD |
| G |
Hras |
Harvey rat sarcoma virus oncogene |
|
|
ISS |
1 |
201,385,705 |
201,388,987 |
RGD:7240710 |
OMIM |
| G |
Hspa1b |
heat shock protein 1B |
|
|
ISS |
20 |
3,955,274 |
3,957,748 |
RGD:7242743 |
RGD |
| G |
Ifng |
interferon gamma |
|
|
ISS |
7 |
57,621,756 |
57,625,792 |
RGD:6893349 |
RGD |
| G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
|
|
ISS |
14 |
87,959,153 |
87,967,085 |
RGD:2290028 |
RGD |
| G |
Il1b |
interleukin 1 beta |
|
Disease_progression |
ISS |
3 |
116,964,422 |
116,970,867 |
RGD:7175327 |
RGD |
| G |
Il1rn |
interleukin 1 receptor antagonist |
|
Susceptibility |
ISS |
3 |
2,607,800 |
2,613,216 |
RGD:6907081 |
RGD |
| G |
Il1rn |
interleukin 1 receptor antagonist |
|
Susceptibility |
ISS |
3 |
2,607,800 |
2,613,216 |
RGD:6907367 |
RGD |
| G |
Jup |
junction plakoglobin |
|
Disease_progression |
ISS |
10 |
89,307,938 |
89,335,254 |
RGD:2289818 |
RGD |
| G |
Jup |
junction plakoglobin |
|
Disease_progression |
ISS |
10 |
89,307,938 |
89,335,254 |
RGD:2301748 |
RGD |
| G |
Kdr |
kinase insert domain receptor |
|
|
ISS |
|
|
|
RGD:2301758 |
RGD |
| G |
Kdr |
kinase insert domain receptor |
|
Severity |
ISS |
|
|
|
RGD:2291949 |
RGD |
| G |
Kiss1 |
KiSS-1 metastasis-suppressor |
|
|
ISS |
13 |
46,244,786 |
46,247,288 |
RGD:2292136 |
RGD |
| G |
Kit |
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog |
|
|
ISS |
14 |
34,906,043 |
34,984,819 |
RGD:2292430 |
RGD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
|
ISS |
4 |
182,869,242 |
182,895,106 |
RGD:1600467 |
RGD |
| G |
Kras |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog |
|
|
ISS |
4 |
182,869,242 |
182,895,106 |
RGD:7240710 |
OMIM |
| G |
Krt5 |
keratin 5 |
|
|
IEP |
|
|
|
RGD:1600196 |
RGD |
| G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
|
|
ISS |
10 |
52,009,149 |
52,041,599 |
RGD:2306057 |
RGD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
Susceptibility |
ISS |
1 |
196,629,366 |
196,866,937 |
RGD:2317672 |
RGD |
| G |
Mki67 |
antigen identified by monoclonal antibody Ki-67 |
|
|
IEP |
1 |
195,310,027 |
195,336,224 |
RGD:2317708 |
RGD |
| G |
Mlh1 |
mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) |
|
Disease_progression |
ISS |
8 |
115,616,396 |
115,653,471 |
RGD:2293518 |
RGD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
|
ISS |
8 |
4,333,773 |
4,354,284 |
RGD:7207077 |
RGD |
| G |
Mmp1 |
matrix metallopeptidase 1 (interstitial collagenase) |
|
Severity |
ISS |
8 |
4,333,773 |
4,354,284 |
RGD:7207140 |
RGD |
| G |
Mmp13 |
matrix metallopeptidase 13 |
|
|
ISS |
8 |
4,158,887 |
4,169,166 |
RGD:2293609 |
RGD |
| G |
Mmp2 |
matrix metallopeptidase 2 |
|
|
ISS |
19 |
15,246,036 |
15,275,061 |
RGD:2290395 |
RGD |
| G |
Mmp9 |
matrix metallopeptidase 9 |
|
|
ISS |
3 |
155,985,473 |
155,993,433 |
RGD:2290395 |
RGD |
| G |
Mre11a |
MRE11 meiotic recombination 11 homolog A (S. cerevisiae) |
|
Susceptibility |
ISS |
8 |
11,588,409 |
11,632,483 |
RGD:2317733 |
RGD |
| G |
Msh2 |
mutS homolog 2 (E. coli) |
|
|
ISS |
6 |
11,199,906 |
11,258,350 |
RGD:2293502 |
RGD |
| G |
Msh2 |
mutS homolog 2 (E. coli) |
|
Disease_progression |
ISS |
6 |
11,199,906 |
11,258,350 |
RGD:2293503 |
RGD |
| G |
Mt-atp8 |
mitochondrially encoded ATP synthase 8 |
|
|
ISS |
MT |
7,758 |
7,961 |
RGD:2302294 |
RGD |
| G |
Mt-cyb |
mitochondrially encoded cytochrome b |
|
|
ISS |
MT |
14,136 |
15,278 |
RGD:2298953 |
RGD |
| G |
Mt-nd2 |
mitochondrially encoded NADH dehydrogenase 2 |
|
|
ISS |
MT |
3,904 |
4,942 |
RGD:2302294 |
RGD |
| G |
Mthfr |
methylenetetrahydrofolate reductase (NAD(P)H) |
|
Susceptibility |
ISS |
5 |
165,112,850 |
165,126,885 |
RGD:6893521 |
RGD |
| G |
Mthfr |
methylenetetrahydrofolate reductase (NAD(P)H) |
|
Susceptibility |
ISS |
5 |
165,112,850 |
165,126,885 |
RGD:6893457 |
RGD |
| G |
Mthfr |
methylenetetrahydrofolate reductase (NAD(P)H) |
|
No_Association |
ISS |
5 |
165,112,850 |
165,126,885 |
RGD:6893597 |
RGD |
| G |
Mthfr |
methylenetetrahydrofolate reductase (NAD(P)H) |
|
Susceptibility |
ISS |
5 |
165,112,850 |
165,126,885 |
RGD:6893516 |
RGD |
| G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
|
Susceptibility |
ISS |
17 |
68,782,708 |
68,867,101 |
RGD:6893521 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
Disease_progression |
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7207427 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
|
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7207418 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
Susceptibility |
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7207401 |
RGD |
| G |
Nedd4 |
neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase |
|
|
ISS |
8 |
77,252,500 |
77,337,402 |
RGD:2302550 |
RGD |
| G |
Nme1 |
NME/NM23 nucleoside diphosphate kinase 1 |
|
|
ISS |
10 |
82,591,705 |
82,601,075 |
RGD:2299071 |
RGD |
| G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
|
|
ISS |
10 |
82,582,766 |
82,588,269 |
RGD:2299071 |
RGD |
| G |
Nos3 |
nitric oxide synthase 3, endothelial cell |
|
|
ISS |
4 |
6,158,847 |
6,179,441 |
RGD:2292089 |
RGD |
| G |
Phb |
prohibitin |
|
|
IEP |
|
|
|
RGD:2292407 |
RGD |
| G |
Plau |
plasminogen activator, urokinase |
|
Treatment |
IED |
15 |
3,680,072 |
3,686,232 |
RGD:4144867 |
RGD |
| G |
Plau |
plasminogen activator, urokinase |
|
|
ISS |
15 |
3,680,072 |
3,686,232 |
RGD:7241144 |
RGD |
| G |
Plau |
plasminogen activator, urokinase |
|
|
ISS |
15 |
3,680,072 |
3,686,232 |
RGD:7241213 |
RGD |
| G |
Plk1 |
polo-like kinase 1 |
|
Severity |
ISS |
1 |
181,002,811 |
181,012,741 |
RGD:2299938 |
RGD |
| G |
Plk1 |
polo-like kinase 1 |
|
|
ISS |
1 |
181,002,811 |
181,012,741 |
RGD:2299940 |
RGD |
| G |
Pms2 |
postmeiotic segregation increased 2 (S. cerevisiae) |
|
Susceptibility |
ISS |
12 |
11,004,507 |
11,028,754 |
RGD:2315025 |
RGD |
| G |
Pparg |
peroxisome proliferator-activated receptor gamma |
|
|
IEP |
4 |
151,492,220 |
151,617,331 |
RGD:2301870 |
RGD |
| G |
Prkca |
protein kinase C, alpha |
|
Disease_progression |
ISS |
10 |
97,367,196 |
97,638,910 |
RGD:2298669 |
RGD |
| G |
Prkca |
protein kinase C, alpha |
|
Severity |
ISS |
10 |
97,367,196 |
97,638,910 |
RGD:2292455 |
RGD |
| G |
Pten |
phosphatase and tensin homolog |
|
Disease_progression |
ISS |
1 |
236,771,027 |
236,837,261 |
RGD:2291891 |
RGD |
| G |
Pten |
phosphatase and tensin homolog |
|
|
ISS |
1 |
236,771,027 |
236,837,261 |
RGD:2292515 |
RGD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
Disease_progression |
ISS |
13 |
64,427,288 |
64,432,978 |
RGD:5508302 |
RGD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
Susceptibility |
ISS |
13 |
64,427,288 |
64,432,978 |
RGD:2300127 |
RGD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
|
ISS |
13 |
64,427,288 |
64,432,978 |
RGD:2300200 |
RGD |
| G |
Ralbp1 |
ralA binding protein 1 |
|
|
ISS |
9 |
104,617,400 |
104,653,856 |
RGD:2324917 |
RGD |
| G |
Rassf1 |
Ras association (RalGDS/AF-6) domain family member 1 |
|
|
ISS |
8 |
112,798,863 |
112,810,004 |
RGD:2299860 |
RGD |
| G |
Rassf1 |
Ras association (RalGDS/AF-6) domain family member 1 |
|
|
ISS |
8 |
112,798,863 |
112,810,004 |
RGD:2291977 |
RGD |
| G |
Rb1 |
retinoblastoma 1 |
|
Disease_progression |
ISS |
15 |
53,828,881 |
53,962,099 |
RGD:2299888 |
RGD |
| G |
Rb1 |
retinoblastoma 1 |
|
|
ISS |
15 |
53,828,881 |
53,962,099 |
RGD:7240710 |
OMIM |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
|
ISS |
1 |
208,262,669 |
208,273,148 |
RGD:2293094 |
RGD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
Disease_progression |
ISS |
1 |
208,262,669 |
208,273,148 |
RGD:2298753 |
RGD |
| G |
Retn |
resistin |
|
|
ISS |
12 |
2,499,630 |
2,501,370 |
RGD:7207154 |
RGD |
| G |
Rhoa |
ras homolog family member A |
|
Disease_progression |
ISS |
|
|
|
RGD:2298872 |
RGD |
| G |
Rrm2 |
ribonucleotide reductase M2 |
|
|
IEP |
6 |
42,350,541 |
42,356,748 |
RGD:5133688 |
RGD |
| G |
Runx3 |
runt-related transcription factor 3 |
|
|
ISS |
5 |
153,950,116 |
153,973,141 |
RGD:2302553 |
RGD |
| G |
S100a8 |
S100 calcium binding protein A8 |
|
|
IEP |
2 |
182,961,994 |
182,962,513 |
RGD:2316906 |
RGD |
| G |
S100a9 |
S100 calcium binding protein A9 |
|
|
IEP |
2 |
182,985,466 |
182,988,147 |
RGD:2316906 |
RGD |
| G |
S100b |
S100 calcium binding protein B |
|
|
IEP |
20 |
12,791,440 |
12,824,508 |
RGD:2316906 |
RGD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
|
ISS |
12 |
20,931,996 |
20,942,374 |
RGD:4144867 |
RGD |
| G |
Sfn |
stratifin |
|
Disease_progression |
ISS |
5 |
151,475,395 |
151,479,996 |
RGD:2299928 |
RGD |
| G |
Slc11a1 |
solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 |
|
Disease_progression |
ISS |
9 |
73,714,692 |
73,725,523 |
RGD:5684951 |
RGD |
| G |
Smad2 |
SMAD family member 2 |
|
|
ISS |
18 |
73,180,520 |
73,241,707 |
RGD:2299964 |
RGD |
| G |
Smad4 |
SMAD family member 4 |
|
|
ISS |
18 |
70,432,705 |
70,461,541 |
RGD:2299972 |
RGD |
| G |
Socs1 |
suppressor of cytokine signaling 1 |
|
Disease_progression |
ISS |
10 |
4,819,971 |
4,820,609 |
RGD:2298906 |
RGD |
| G |
Socs1 |
suppressor of cytokine signaling 1 |
|
|
ISS |
10 |
4,819,971 |
4,820,609 |
RGD:2298903 |
RGD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
|
ISS |
1 |
41,862,997 |
41,870,327 |
RGD:7175539 |
RGD |
| G |
Sox4 |
SRY (sex determining region Y)-box 4 |
|
|
ISS |
17 |
42,172,863 |
42,177,590 |
RGD:1581304 |
RGD |
| G |
Sparc |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
|
ISS |
10 |
40,809,730 |
40,831,481 |
RGD:2300021 |
RGD |
| G |
Sparc |
secreted protein, acidic, cysteine-rich (osteonectin) |
|
Disease_progression |
ISS |
10 |
40,809,730 |
40,831,481 |
RGD:2300024 |
RGD |
| G |
Spink1 |
serine peptidase inhibitor, Kazal type 1 |
|
Disease_progression |
ISS |
18 |
37,090,934 |
37,099,835 |
RGD:2300384 |
RGD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
|
ISS |
|
|
|
RGD:6903265 |
RGD |
| G |
Sult1a1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
|
ISS |
1 |
185,829,205 |
185,832,725 |
RGD:1581442 |
RGD |
| G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
|
|
ISS |
14 |
82,746,460 |
82,760,864 |
RGD:7240710 |
OMIM |
| G |
Terc |
telomerase RNA component |
|
|
ISS |
2 |
117,234,446 |
117,234,833 |
RGD:2291986 |
RGD |
| G |
Terc |
telomerase RNA component |
|
Disease_progression |
ISS |
2 |
117,234,446 |
117,234,833 |
RGD:2291967 |
RGD |
| G |
Tert |
telomerase reverse transcriptase |
|
|
ISS |
1 |
30,445,180 |
30,465,942 |
RGD:2291986 |
RGD |
| G |
Tff1 |
trefoil factor 1 |
|
|
ISS |
20 |
9,526,674 |
9,530,534 |
RGD:2291996 |
RGD |
| G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
|
|
ISS |
5 |
63,976,868 |
64,034,058 |
RGD:2302036 |
RGD |
| G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
|
|
ISS |
10 |
108,310,473 |
108,358,821 |
RGD:2290395 |
RGD |
| G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
|
Disease_progression |
ISS |
10 |
108,310,473 |
108,358,821 |
RGD:2298521 |
RGD |
| G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
|
|
ISS |
7 |
19,677,144 |
19,727,072 |
RGD:2290411 |
RGD |
| G |
Tlr2 |
toll-like receptor 2 |
|
|
ISS |
2 |
175,607,990 |
175,613,992 |
RGD:7207893 |
RGD |
| G |
Tlr4 |
toll-like receptor 4 |
|
Treatment |
ISS |
5 |
83,564,100 |
83,577,735 |
RGD:7240556 |
RGD |
| G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
|
|
ISS |
9 |
47,519,306 |
47,811,472 |
RGD:2290489 |
RGD |
| G |
Top2a |
topoisomerase (DNA) II alpha |
|
Disease_progression |
ISS |
10 |
87,771,337 |
87,800,960 |
RGD:2315121 |
RGD |
| G |
Tp53 |
tumor protein p53 |
|
Disease_progression |
ISS |
10 |
56,399,721 |
56,411,150 |
RGD:2290536 |
RGD |
| G |
Tp63 |
tumor protein p63 |
|
Disease_progression |
ISS |
11 |
76,900,622 |
77,200,251 |
RGD:2315430 |
RGD |
| G |
Tp73 |
tumor protein p73 |
|
Disease_progression |
ISS |
5 |
170,848,979 |
171,078,739 |
RGD:2291836 |
RGD |
| G |
Tymp |
thymidine phosphorylase |
|
Disease_progression |
ISS |
7 |
127,666,518 |
127,671,624 |
RGD:2293716 |
RGD |
| G |
Tyms |
thymidylate synthetase |
|
|
IED |
9 |
112,604,912 |
112,617,706 |
RGD:2317413 |
RGD |
| G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
|
Induced |
ISS |
10 |
14,509,948 |
14,524,551 |
RGD:2301343 |
RGD |
| G |
Vegfc |
vascular endothelial growth factor C |
|
Disease_progression |
ISS |
16 |
40,624,435 |
40,739,692 |
RGD:2315482 |
RGD |
| G |
Vhl |
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
|
|
IEP |
4 |
149,529,396 |
149,536,289 |
RGD:2325183 |
RGD |
| G |
Wif1 |
Wnt inhibitory factor 1 |
|
Disease_progression |
ISS |
7 |
60,330,517 |
60,400,697 |
RGD:727214 |
RGD |
| G |
Wif1 |
Wnt inhibitory factor 1 |
|
Disease_progression |
ISS |
7 |
60,330,517 |
60,400,697 |
RGD:2291868 |
RGD |
| G |
Wnt7b |
wingless-type MMTV integration site family, member 7B |
|
|
ISS |
7 |
123,533,713 |
123,554,333 |
RGD:2299932 |
RGD |
| G |
Xrcc1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
|
No_Association |
ISS |
1 |
79,834,167 |
79,860,300 |
RGD:2302572 |
RGD |
| G |
Xrcc1 |
X-ray repair complementing defective repair in Chinese hamster cells 1 |
|
Susceptibility |
ISS |
1 |
79,834,167 |
79,860,300 |
RGD:2302568 |
RGD |
| S |
DA |
DA |
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
WAGR Syndrome
|
| G |
Wt1 |
Wilms tumor 1 |
|
|
IEA |
3 |
90,529,704 |
90,577,280 |
RGD:1331525 |
RGD |
Wilms Tumor
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
Disease_progression |
ISS |
4 |
21,709,855 |
21,796,628 |
RGD:2315560 |
RGD |
| G |
Apoc3 |
apolipoprotein C-III |
|
|
ISS |
|
|
|
RGD:7207220 |
RGD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
Disease_progression |
ISS |
3 |
143,129,087 |
143,180,199 |
RGD:1643482 |
RGD |
| G |
Bmp7 |
bone morphogenetic protein 7 |
|
|
IEP |
3 |
163,723,429 |
163,799,567 |
RGD:2289034 |
RGD |
| G |
Brca2 |
breast cancer 2, early onset |
|
Susceptibility |
ISS |
12 |
4,282,952 |
4,323,693 |
RGD:2289049 |
RGD |
| G |
Brca2 |
breast cancer 2, early onset |
|
|
ISS |
12 |
4,282,952 |
4,323,693 |
RGD:7240710 |
OMIM |
| G |
Ccnd2 |
cyclin D2 |
|
|
ISS |
4 |
163,523,817 |
163,546,501 |
RGD:2289153 |
RGD |
| G |
Cd44 |
Cd44 molecule |
|
|
ISS |
3 |
88,022,962 |
88,110,352 |
RGD:2289361 |
RGD |
| G |
Cdk15 |
cyclin-dependent kinase 15 |
|
|
ISS |
9 |
57,840,625 |
57,930,096 |
RGD:2316755 |
RGD |
| G |
Cdk4 |
cyclin-dependent kinase 4 |
|
Disease_progression |
ISS |
|
|
|
RGD:2289153 |
RGD |
| G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
|
Disease_progression |
ISS |
4 |
171,841,705 |
171,846,506 |
RGD:2293605 |
RGD |
| G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
|
|
ISS |
5 |
108,908,749 |
108,916,380 |
RGD:2289679 |
RGD |
| G |
Cdkn2a_v1 |
cyclin-dependent kinase inhibitor 2A, variant 1 |
|
|
ISS |
|
|
|
RGD:2289679 |
RGD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
|
ISS |
8 |
125,978,161 |
125,987,670 |
RGD:2289833 |
RGD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
|
ISS |
8 |
125,978,161 |
125,987,670 |
RGD:2289834 |
RGD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
|
ISS |
10 |
87,219,157 |
87,242,919 |
RGD:2289932 |
RGD |
| G |
Flt1 |
FMS-related tyrosine kinase 1 |
|
Severity |
ISS |
12 |
7,858,092 |
8,035,966 |
RGD:2289966 |
RGD |
| G |
Gpc3 |
glypican 3 |
|
|
ISS |
X |
139,192,115 |
139,560,649 |
RGD:7240710 |
OMIM |
| G |
H19 |
H19, imprinted maternally expressed transcript (non-protein coding) |
|
Susceptibility |
ISS |
1 |
202,822,925 |
202,825,601 |
RGD:2306181 |
RGD |
| G |
Hif1a |
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
|
Severity |
ISS |
6 |
96,419,024 |
96,463,891 |
RGD:2291911 |
RGD |
| G |
Igf1r |
insulin-like growth factor 1 receptor |
|
|
ISS |
1 |
122,704,976 |
122,990,007 |
RGD:7242789 |
RGD |
| G |
Igf2r |
insulin-like growth factor 2 receptor |
|
|
ISS |
1 |
42,253,273 |
42,341,646 |
RGD:7242956 |
RGD |
| G |
Jup |
junction plakoglobin |
|
Disease_progression |
ISS |
10 |
89,307,938 |
89,335,254 |
RGD:2301745 |
RGD |
| G |
Mthfr |
methylenetetrahydrofolate reductase (NAD(P)H) |
|
Susceptibility |
ISS |
5 |
165,112,850 |
165,126,885 |
RGD:6893546 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
Severity |
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7207840 |
RGD |
| G |
Myc |
myelocytomatosis oncogene |
|
|
ISS |
7 |
98,953,142 |
98,958,060 |
RGD:7207786 |
RGD |
| G |
Pak1 |
p21 protein (Cdc42/Rac)-activated kinase 1 |
|
|
ISS |
1 |
155,057,622 |
155,174,714 |
RGD:2299168 |
RGD |
| G |
Pax2 |
paired box 2 |
|
|
ISS |
1 |
249,804,055 |
249,895,306 |
RGD:2316755 |
RGD |
| G |
Pax2 |
paired box 2 |
|
|
IEP |
1 |
249,804,055 |
249,895,306 |
RGD:2316757 |
RGD |
| G |
Pcna |
proliferating cell nuclear antigen |
|
Disease_progression |
ISS |
3 |
120,008,715 |
120,012,589 |
RGD:2315007 |
RGD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
|
ISS |
13 |
64,427,288 |
64,432,978 |
RGD:2300206 |
RGD |
| G |
Serpinf1 |
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 |
|
|
ISS |
10 |
62,713,441 |
62,739,444 |
RGD:2312354 |
RGD |
| G |
Stat1 |
signal transducer and activator of transcription 1 |
|
|
ISS |
9 |
46,455,635 |
46,497,560 |
RGD:2291893 |
RGD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
Disease_progression |
ISS |
10 |
89,821,078 |
89,872,970 |
RGD:2291911 |
RGD |
| G |
Terc |
telomerase RNA component |
|
Disease_progression |
ISS |
2 |
117,234,446 |
117,234,833 |
RGD:2291966 |
RGD |
| G |
Tert |
telomerase reverse transcriptase |
|
Disease_progression |
ISS |
1 |
30,445,180 |
30,465,942 |
RGD:2291966 |
RGD |
| G |
Timp4 |
tissue inhibitor of metalloproteinase 4 |
|
|
ISS |
4 |
151,375,072 |
151,381,591 |
RGD:2290439 |
RGD |
| G |
Top2a |
topoisomerase (DNA) II alpha |
|
|
ISS |
10 |
87,771,337 |
87,800,960 |
RGD:2315132 |
RGD |
| G |
Top2a |
topoisomerase (DNA) II alpha |
|
|
ISS |
10 |
87,771,337 |
87,800,960 |
RGD:2315131 |
RGD |
| G |
Tp73 |
tumor protein p73 |
|
|
ISS |
5 |
170,848,979 |
171,078,739 |
RGD:2291834 |
RGD |
| G |
Vegfc |
vascular endothelial growth factor C |
|
Disease_progression |
ISS |
16 |
40,624,435 |
40,739,692 |
RGD:2315481 |
RGD |
| G |
Vhl |
von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase |
|
|
IEP |
4 |
149,529,396 |
149,536,289 |
RGD:625549 |
RGD |
| G |
Wif1 |
Wnt inhibitory factor 1 |
|
|
ISS |
7 |
60,330,517 |
60,400,697 |
RGD:2291870 |
RGD |
| G |
Wt1 |
Wilms tumor 1 |
|
|
ISS |
3 |
90,529,704 |
90,577,280 |
RGD:2315545 |
RGD |
| G |
Wt1 |
Wilms tumor 1 |
|
|
ISS |
3 |
90,529,704 |
90,577,280 |
RGD:2315544 |
RGD |
| G |
Wt1 |
Wilms tumor 1 |
|
|
IEA |
3 |
90,529,704 |
90,577,280 |
RGD:1331525 |
RGD |
| G |
Wt1 |
Wilms tumor 1 |
|
|
ISS |
3 |
90,529,704 |
90,577,280 |
RGD:7240710 |
OMIM |
Term paths to the root
|